Dr. Michael Emmons, shown with his committee, successfully defended his dissertation on August 16, 2012. From left to right: Dissertation Chair Larry Boise, Emory School of Medicine; Major Professor Lori Hazlehurst, Michael Emmons; Committee members John Koomen, Mark McLaughlin and Steve Eschrich. Dr. Emmons initially joined biotech firm Modulation Therapeutics but recently returned to Moffitt as a postdoc in the lab of Dr. Keiran Smalley.
Dr. Emmons Publication Record while in the Program:
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved a4 integrin expression and a compromised CAM-DR phenotype.Mol Cancer Ther. 2011 Dec;10(12):2257-66.
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009 Sep 1;69(17):6899-905. Epub 2009 Aug 18.
Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther. 2009 Aug;8(8):2441-51.
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther. 2008 Oct;7(10):3169-75.
Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochem Pharmacol. 2006 Jun 28;72(1):11-8.
Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006 Feb 15;66(4):2338-45.
Dr. Emmons Publication Record since graduation:
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.
J Cancer. 2013 Sep 10;4(8):614-25. PMID: 24155773
Engel BE, Welsh E, Emmons MF, Santiago-Cardona PG, Cress WD. Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors. Cell Death Dis. 2013 Nov 28;4:e938.PMID:24287699
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Mol Cancer Ther. 2013 Nov;12(11):2446-58PMID:24048737
Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Adv Pharmacol. 2012;65:143-89.PMID: 22959026